BidaskClub upgraded shares of Quidel (NASDAQ:QDEL) from a buy rating to a strong-buy rating in a report issued on Monday, February 4th.
Several other equities research analysts have also commented on the company. Zacks Investment Research lowered Quidel from a buy rating to a hold rating in a research report on Friday, January 25th. ValuEngine upgraded Quidel from a sell rating to a hold rating in a report on Wednesday, January 2nd. Raymond James cut their price target on Quidel from $80.00 to $70.00 and set a strong-buy rating on the stock in a report on Tuesday, December 11th. Canaccord Genuity lowered Quidel to a buy rating in a report on Tuesday, December 11th. Finally, Craig Hallum lowered Quidel from a buy rating to a hold rating and cut their price target for the stock from $80.00 to $51.00 in a report on Monday, December 10th. Three investment analysts have rated the stock with a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $71.50.
Shares of QDEL stock opened at $67.80 on Monday. The stock has a market capitalization of $2.67 billion, a PE ratio of 24.04, a P/E/G ratio of 0.98 and a beta of 1.27. The company has a quick ratio of 0.86, a current ratio of 1.21 and a debt-to-equity ratio of 0.12. Quidel has a 1-year low of $42.13 and a 1-year high of $77.63.
Quidel (NASDAQ:QDEL) last announced its earnings results on Wednesday, February 13th. The company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.54 by $0.21. Quidel had a return on equity of 31.73% and a net margin of 14.20%. The company had revenue of $132.59 million for the quarter, compared to analyst estimates of $132.26 million. During the same quarter in the prior year, the company earned $0.56 EPS. The firm’s revenue for the quarter was up 15.4% compared to the same quarter last year. As a group, research analysts predict that Quidel will post 2.77 earnings per share for the current year.
In other Quidel news, CEO Douglas C. Bryant sold 25,250 shares of the firm’s stock in a transaction on Tuesday, January 29th. The stock was sold at an average price of $55.09, for a total value of $1,391,022.50. Following the completion of the sale, the chief executive officer now directly owns 319,563 shares of the company’s stock, valued at $17,604,725.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Douglas C. Bryant sold 22,153 shares of the firm’s stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $65.62, for a total value of $1,453,679.86. Following the completion of the transaction, the chief executive officer now directly owns 322,006 shares of the company’s stock, valued at $21,130,033.72. The disclosure for this sale can be found here. Insiders have sold 235,254 shares of company stock valued at $15,276,431 over the last ninety days. 16.70% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the stock. Northern Trust Corp boosted its stake in Quidel by 15.4% during the second quarter. Northern Trust Corp now owns 423,108 shares of the company’s stock valued at $28,136,000 after buying an additional 56,538 shares during the period. Gagnon Securities LLC increased its holdings in shares of Quidel by 305.9% in the fourth quarter. Gagnon Securities LLC now owns 120,035 shares of the company’s stock worth $5,860,000 after buying an additional 90,466 shares during the period. United Services Automobile Association increased its holdings in shares of Quidel by 26.4% in the second quarter. United Services Automobile Association now owns 7,382 shares of the company’s stock worth $491,000 after buying an additional 1,542 shares during the period. Vanguard Group Inc. increased its holdings in shares of Quidel by 5.5% in the third quarter. Vanguard Group Inc. now owns 2,929,387 shares of the company’s stock worth $190,909,000 after buying an additional 152,702 shares during the period. Finally, Trexquant Investment LP purchased a new position in shares of Quidel in the third quarter worth about $689,000. 88.89% of the stock is owned by institutional investors.
Quidel Company Profile
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
Featured Article: What is a good rate of return for a mutual fund?
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.